FDA Expands IBRANCE Use : Pfizer Secures Landmark Approval for HR+/HER2+ Metastatic Breast Cancer
25 June 2026

FDA Expands IBRANCE Use : Pfizer Secures Landmark Approval for HR+/HER2+ Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved a new indication for Pfizer's IBRANCE (palbociclib), allowing its use in combination with trastuzumab, with or without pertuzumab, and endocrine therapy as maintenance treatment for adults with hormone receptor-positive (HR+), HER2-positive (HER2+) locally advanced or metastatic breast cancer following induction therapy. The approval marks a significant expansion for the widely used CDK4/6 inhibitor.

Trodelvy Gains Simultaneous US FDA and EU Approval as First-Line Treatment for Metastatic Triple-Negative Breast Cancer
25 June 2026
Trodelvy Gains Simultaneous US FDA and EU Approval as First-Line Treatment for Metastatic Triple-Negative Breast Cancer
Gilead Sciences has achieved a major milestone in breast cancer treatment as Trodelvy® (sacituzumab govitecan-hziy) received approvals from both the U.S. Food and Drug Administration (FDA) and the European Commission (EC) for use as a first-line therapy in metastatic triple-negative breast cancer
WHO Moves to Establish Global Standards for Herbal Medicines Through International Pharmacopoeia Initiative
25 June 2026
WHO Moves to Establish Global Standards for Herbal Medicines Through International Pharmacopoeia Initiative

The World Health Organization (WHO) has taken another significant step toward strengthening the quality, safety, and regulation of herbal medicines by advancing the development of an International Herbal Pharmacopoeia (IHP). During the 5th WHO Expert Meeting held in Hong Kong SAR (China) from 16–18 June 2026, experts from all six WHO regions met to accelerate the creation of globally harmonized standards for herbal medicines.

EU Invests 15 Million euro in Phage Therapy Research to Combat Recurrent Urinary Tract Infections
25 June 2026
EU Invests 15 Million euro in Phage Therapy Research to Combat Recurrent Urinary Tract Infections

The European Union has awarded 15 million euro under its Horizon Europe research and innovation program to launch REPhRAME, an ambitious international project aimed at developing a new treatment strategy for recurrent urinary tract infections (UTIs). Coordinated by Universitätsmedizin Frankfurt under the leadership of Prof. Dr. Maria J.G.T. Vehreschild, the five-year project will evaluate phage therapy as a potential alternative to antibiotics in patients suffering from recurrent bacterial infections.

New Strategy May Help Prevent Cancer Relapse After KRAS-Targeted Therapy, Study Finds
25 June 2026
New Strategy May Help Prevent Cancer Relapse After KRAS-Targeted Therapy, Study Finds

Researchers from Chiba University, Japan, have identified a promising strategy that could help prevent cancer from returning after treatment with KRAS-targeted drugs. The study reveals that a small population of cancer cells, known as drug-tolerant persister cells (DTPs), survives KRAS inhibitor therapy by rewiring its metabolism. By targeting these newly discovered survival mechanisms, scientists believe it may be possible to eliminate these residual cells and reduce the risk of relapse.

Opportunity for MPharm, MSc, MTech candidates at BRIC-Institute of Life Sciences
24 June 2026
Opportunity for MPharm, MSc, MTech candidates at BRIC-Institute of Life Sciences
Candidates having M.Sc. / M. Tech / M. Pharm. / M.V.Sc. or equivalent qualification in Life Sciences or allied subjects (Biochemistry / Biotechnology / Virology / Microbiology, etc.) with a minimum of 55% aggregate marks (relaxation will be given as per GOI guideline).
Pharma and Clinical Research Recruitment at Tata Memorial Hospital
24 June 2026
Pharma and Clinical Research Recruitment at Tata Memorial Hospital
Graduate Degree in Sciences / B.Pharm & Post Graduate Diploma in Clinical Research is Mandatory.
ANRF-PMECRG Life Sciences, Microbiology, Bioinformatics, Biochemistry, Biotechnology Fellowship
24 June 2026
ANRF-PMECRG Life Sciences, Microbiology, Bioinformatics, Biochemistry, Biotechnology Fellowship
Four-Year Bachelors Degree/ Masters Degree in Microbiology/ Bioinformatics/ Biochemistry/ Biotechnology/ Botany/Environmental Sciences/ or other relevant fields in Life Sciences with minimum 55% marks or equivalent grade.
Career for Life Sciences professionals at THSTI
24 June 2026
Career for Life Sciences professionals at THSTI
Post-Graduation degree, including the integrated PG degree, in any branch of Life Sciences from a recognized university.
Interview for Pharma and Science candidates in QA, QC, Manufacturing at Sun Pharma
24 June 2026
Interview for Pharma and Science candidates in QA, QC, Manufacturing at Sun Pharma
Sun Pharma is India’s No. 1 pharmaceutical company and a leading global player in specialty medicines. With over 40 manufacturing facilities and a diverse portfolio, we deliver high-quality medicines across 100 countries.